drugset / Trial / NCT03333343
Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The study purpose is to evaluate the safety, tolerability, and preliminary efficacy of the addition of INC280, trametinib, ribociclib, gefitinib, or LXH254 to EGF816 in adult patients with advanced Epidermal growth factor receptor- mutant (EGFR-mutant) non-small cell lung cancer (NSCLC).
Timeline
- Start
- 2018-01-29
- Primary completion
- 2026-10-05
- Completion
- 2026-10-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capmatinib | Small molecule | — | — |
| Subject | Gefitinib | Small molecule | — | — |
| Subject | Naporafenib | Small molecule | — | — |
| Subject | Nazartinib | Small molecule | — | — |
| Subject | Ribociclib | Small molecule | — | — |
| Subject | Trametinib | Small molecule | — | — |